AU2013276993B9 - IVIG Modulations of Chemokines for Treatment of Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease - Google Patents

IVIG Modulations of Chemokines for Treatment of Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease

Info

Publication number
AU2013276993B9
AU2013276993B9 AU2013276993A AU2013276993A AU2013276993B9 AU 2013276993 B9 AU2013276993 B9 AU 2013276993B9 AU 2013276993 A AU2013276993 A AU 2013276993A AU 2013276993 A AU2013276993 A AU 2013276993A AU 2013276993 B9 AU2013276993 B9 AU 2013276993B9
Authority
AU
Australia
Prior art keywords
disease
ivig
modulations
chemokines
parkinson
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013276993A
Other versions
AU2013276993A1 (en
AU2013276993B2 (en
Inventor
Hartmut Ehrlich
Irina Elovaara
Birgit Reipert
Hans-Peter Schwarz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Baxalta GmbH
Takeda Pharmaceutical Co Ltd
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008286361A external-priority patent/AU2008286361B2/en
Application filed by Baxalta GmbH, Takeda Pharmaceutical Co Ltd, Baxalta Inc filed Critical Baxalta GmbH
Priority to AU2013276993A priority Critical patent/AU2013276993B9/en
Publication of AU2013276993A1 publication Critical patent/AU2013276993A1/en
Assigned to Baxalta GmbH, BAXALTA INCORPORATED reassignment Baxalta GmbH Request for Assignment Assignors: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
Application granted granted Critical
Publication of AU2013276993B2 publication Critical patent/AU2013276993B2/en
Publication of AU2013276993B9 publication Critical patent/AU2013276993B9/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: Baxalta GmbH, BAXALTA INCORPORATED
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

AU2013276993A 2007-08-13 2013-12-24 IVIG Modulations of Chemokines for Treatment of Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease Ceased AU2013276993B9 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013276993A AU2013276993B9 (en) 2007-08-13 2013-12-24 IVIG Modulations of Chemokines for Treatment of Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60/955,610 2007-08-13
AU2008286361A AU2008286361B2 (en) 2007-08-13 2008-08-11 IVIG modulation of chemokines for treatment of multiple sclerosis, Alzheimer's disease, and Parkinson's disease
AU2013276993A AU2013276993B9 (en) 2007-08-13 2013-12-24 IVIG Modulations of Chemokines for Treatment of Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2008286361A Division AU2008286361B2 (en) 2007-08-13 2008-08-11 IVIG modulation of chemokines for treatment of multiple sclerosis, Alzheimer's disease, and Parkinson's disease

Publications (3)

Publication Number Publication Date
AU2013276993A1 AU2013276993A1 (en) 2014-01-23
AU2013276993B2 AU2013276993B2 (en) 2016-03-31
AU2013276993B9 true AU2013276993B9 (en) 2016-04-21

Family

ID=

Similar Documents

Publication Publication Date Title
EP1940373B8 (en) 1-fluoro-1-deoxy-scyllo-inositol for the treatment of alzheimer's disease
HK1215960A1 (en) Improved modalities for the treatment of degenerative diseases of the retina
EP2195084A4 (en) Method of treating parkinson's disease and other movement disorders
SI2104682T1 (en) Diagnosis and treatment of alzheimer's and other neurodementing diseases
EP2260109A4 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
PL2197883T3 (en) Catecholamine derivative useful for the treatment of parkinson's disease
ZA201008484B (en) Rasagiline for parkinson's disease modification
HK1166983A1 (en) Solid forms comprising compounds for the treatment of diseases or disorders, compositions thereof, and use therewith
HUE043807T2 (en) Glyx for use in the treatment of alzheimer's disease, parkinson's disease or huntington's disease
EP2160100B8 (en) Treatment of graft-versus-host disease
EP2268647A4 (en) Compounds and compositions for the detection and treatment of alzheimer's disease and related disorders
EP2139460A4 (en) Compositions and methods for the diagnosis, treatment, and prevention of amyotrophic lateral sclerosis and related neurological diseases
EP2320939A4 (en) Tissue kallikrein for the treatment of parkinson's disease
EP2187898B8 (en) Use of viral vectors carrying the cyp46a1 gene for the treatment of alzheimer's disease
EP1888056A4 (en) Use of ladostigil for the treatment of multiple sclerosis
GB0611240D0 (en) The treatment of increased sebum production
GB0611241D0 (en) The treatment of increased sebum production
WO2010085799A9 (en) Compositions and method for the treatment of parkinson's disease
ZA201103070B (en) Process for treatment of rheumatoid arthritis, tremos/parkinson's disease, multiple sclerosis and non-viral based cancers
WO2006136454A3 (en) Use of inhibitors of n-methyl transferases for the therapy of parkinson's disease
EP2214488A4 (en) Compositions and methods for treating parkinson's disease and related disorders
AU2013276993B9 (en) IVIG Modulations of Chemokines for Treatment of Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease
WO2011008675A3 (en) Catecholamine compounds, compositions, and formulations, and methods of using the same
PL2307380T3 (en) N'-nitroxyalkylnicotinamides for the treatment of cardiovascular diseases
AU2008339005A8 (en) 3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of Alzheimer's disease